Back to Journals » Vascular Health and Risk Management » Volume 2 » Issue 1

Effects of eprosartan on target organ protection

Authors Alejandro de la Sierra

Published 15 March 2006 Volume 2006:2(1) Pages 79—85


Alejandro de la Sierra

Hypertension Unit, Department of Internal Medicine, Hospital Clínic, IDIBAPS, University of Barcelona, Spain

Abstract: Hypertension is the most important cardiovascular risk factor for stroke. Blood pressure reduction by antihypertensive treatment is clearly efficacious in the prevention of stroke (both primary and secondary), although no clear differences have yet been observed between antihypertensive drug classes. However, a recent study reported the clear superiority of the angiotensin-receptor blocker eprosartan over the calcium channel blocker nitrendipine in cardiovascular protection of hypertensive patients with a previous stroke. Comparative studies using angiotensin-receptor blockers have also suggested the superiority of this class of drugs on primary stroke prevention. This effect may be linked to their beneficial actions on left ventricular hypertrophy, atrial enlargement, and supraventricular arrhythmias, endothelial dysfunction, inflammation, and remodelling, as well as a direct neuroprotective effect mediated through the stimulation of the angiotensin II type-2 receptor. In addition, a sympathoinhibition observed with the renin–angiotensin system blockers and particularly demonstrated with eprosartan, may help to explain the better cardiovascular and cerebrovascular protection in comparison with the calcium antagonist nitrendipine.

Keywords: eprosartan, angiotensin-receptor blockers, hypertension, stroke, organ protection

Download Article [PDF]